CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Can-Fite BioPharma Ltd (CANF) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock has experienced significant recent price declines, lacks strong proprietary trading signals, and has mixed sentiment from analysts and technical indicators. While there are positive clinical trial results, the company's financials and trading trends do not currently support a compelling long-term investment case.
The MACD is slightly positive but contracting, RSI is neutral at 44.908, and moving averages are converging, indicating no clear trend. Key support is at 4.117, and resistance is at 6.482. The stock has a high probability of minor gains in the short term but lacks strong upward momentum.
Positive Phase 2a clinical trial results for Namodenoson in pancreatic cancer, showing improved survival rates and tolerability. Financing agreement to enhance liquidity for R&D and clinical trials.
Significant recent price decline (-23.59% in regular market, -17.11% pre-market). Analyst downgrade to Hold due to reverse stock split concerns. Neutral trading sentiment from hedge funds and insiders.
In Q4 2023, revenue remained flat at $155,000, net income was -$1,652,000, and EPS was -4.29, showing no year-over-year growth. Gross margin remained at 100%, but the company is still operating at a loss.
Analyst Jason Kolbert downgraded the stock to Hold from Buy, citing concerns over the reverse stock split. No price target was provided.
